Meda South Africa

Meda Global has approximately 2,600 employees, including 1,550 in sales and marketing and is about the 50th largest pharmaceutical company in the world by sales. As part of global expansion plans, the South African affiliate is the first on the African continent and an indication of European investment confidence in the local economy. Meda’s share has been quoted on the Stockholm Stock Exchange since 1995 and on the NASDAQ OMX Nordic Exchange in Stockholm (Large Cap segment) since 2006

Rotate ADEM on the left to flip through the treatment areas


Heart failure, also known as congestive heart failure (CHF), is a chronic condition in which the heart is unable to pump blood effectively enough to meet the needs of the body.

Read More


Malignant hyperthermia is a life-threatening genetic sensitivity of skeletal muscles to volatile anaesthetics and depolarizing neuromuscular blocking drugs occurring during or after anaesthesia.

Read More


South Africa has the largest incidence of skin cancer in the world. It has 50% more solar radiation than Europe.

Read More


Irritable bowel syndrome (IBS) is a chronic condition of the gastrointestinal tract. Its main symptoms are abdominal pain and altered bowel habits which have no identifiable cause.

Read More